Overview

A Clinical Trial Evaluating the Safety of TD001 In Patients With PSMA-Expressing Metastatic Prostate Cancer

Status:
NOT_YET_RECRUITING
Trial end date:
2029-03-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the safety, tolerability, drug levels (pharmacokinetics) and preliminary antitumor activity of TD001, an antibody-drug conjugate (ADC) targeting prostate-specific membrane antigen (PSMA), in men with metastatic PSMA-expressing castration-resistant prostate cancer (CRPC).
Phase:
PHASE1
Details
Lead Sponsor:
T.O.A.D. Oncology SA